CC
CDAK

Casdin Capital’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Casdin Capital’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-76,688
Closed -$1.16M – 59
2021
Q1 		$1.16M Hold
76,688
– – 0.03% 48
2020
Q4 		$2.48M Buy
+76,688
New +$1.01M 0.07% 50

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Casdin Capital's CDAK Position: Q2 2021 in Review

Casdin Capital sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2021, closing a stake of 76,688 shares — an estimated $1.16M sold.

Casdin Capital first reported a position in CDAK in Q4 2020 and held it in 2 quarters. The position peaked at $2.48M in Q4 2020. 52 funds tracked by Wall St. Rank hold CDAK as of Q2 2021.

  • Casdin Capital reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Casdin Capital sold 76,688 Codiak BioSciences, Inc. Common Stock shares in Q2 2021, an estimated $1.16M.
  • Casdin Capital first reported a position in Codiak BioSciences, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Casdin Capital's Codiak BioSciences, Inc. Common Stock position peaked at $2.48M in Q4 2020.
  • 52 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2021.

Based on Casdin Capital's 13F filing for Q2 2021, filed 16 Aug 2021.